FDA approves AstraZeneca and Daiichi Sankyo's ADC datopotamab deruxtecan for metastatic TNBC.
AstraZeneca and Daiichi Sankyo secured U.S. FDA approval for datopotamab deruxtecan (Dato-DXd), expanding their antibody-drug conjugate portfolio into the competitive metastatic triple-negative breast cancer space. The TROP2-directed therapy offers a new option for heavily pretreated patients. Its entry directly challenges Gilead's established Trodelvy.
Drug Profile
Datopotamab deruxtecan is an antibody-drug conjugate targeting Trophoblast Cell-Surface Antigen 2 (TROP2), a transmembrane protein frequently overexpressed on the surface of TNBC cells. The ADC consists of three components: a humanized anti-TROP2 IgG1 monoclonal antibody, a stable tetrapeptide-based cleavable linker, and a topoisomerase I inhibitor payload (deruxtecan).
Upon binding to TROP2, the ADC is internalized by the cancer cell. The linker is then cleaved by lysosomal enzymes, releasing the potent cytotoxic payload inside the cell to induce DNA damage and apoptosis. Structurally, Dato-DXd leverages the same DXd payload technology as the partnership’s HER2-directed ADC, Enhertu. A key design feature is a drug-to-antibody ratio (DAR) of approximately four, which is engineered to optimize the balance between therapeutic efficacy and systemic toxicity.
Clinical Data
The approval is based on results from the TROPION-Breast01 trial, a global Phase 3 study evaluating Dato-DXd against investigator's choice of single-agent chemotherapy (ICC) in patients with unresectable or metastatic TNBC previously treated with one or two prior lines of systemic therapy.
| Endpoint | Result | Comparator | Trial | | :--- | :--- | :--- | :--- | | Progression-Free Survival (PFS) | 6.9 months | 4.9 months (ICC) | TROPION-Breast01 | | Overall Survival (OS) | 12.1 months | 11.0 months (ICC) | TROPION-Breast01 |
The trial met its primary endpoint of a statistically significant improvement in PFS, with a hazard ratio (HR) of 0.63. The dual primary endpoint of OS was not statistically significant at the time of interim analysis (HR: 0.84), though the data were immature. (https://www.astrazeneca.com/media-centre/press-releases/2023/datopotamab-deruxtecan-showed-statistically-significant-pfs-improvement-in-patients-with-metastatic-breast-cancer-in-tropion-breast01-phase-iii-trial.html)
Global Regulatory Status
Drug-specific status across all four regulatory bodies BrunoSan tracks. Separate from pipeline volume shown in the infobar.
| Regulatory Body | Status | Notes |
|---|---|---|
| Regulatory Body | Status | |
| FDA (U.S.) | ✓ Approved May 25, 2026 | |
| EMA (Europe) | No submission entry detected in BrunoSan DB as of May 25, 2026 | |
| Health Canada | No submission entry detected in BrunoSan DB as of May 25, 2026 | |
| ANVISA (Brazil) | No submission entry detected in BrunoSan DB as of May 25, 2026 |
STATUS
Market Impact
The approval positions datopotamab deruxtecan as a direct competitor to Gilead Sciences' Trodelvy (sacituzumab govitecan-hziy), the first-in-class TROP2-directed ADC in metastatic TNBC. Both drugs target the same antigen, but their differentiation lies in the payload and linker technology. Dato-DXd employs a deruxtecan payload, whereas Trodelvy delivers SN-38, the active metabolite of irinotecan. This structural difference translates to distinct safety and tolerability profiles. The TROPION-Breast01 data suggest Dato-DXd may have a more manageable profile regarding certain adverse events like neutropenia and diarrhea, which could be a key factor in physician choice. However, Trodelvy benefits from a multi-year market head start, established physician familiarity, and a proven overall survival benefit in its pivotal ASCENT trial.
The commercial battle will be fought on clinical differentiation, market access, and sequencing strategies. AstraZeneca and Daiichi Sankyo must leverage Dato-DXd's potential safety advantages to carve out a meaningful share. The lack of a statistically significant OS benefit at the time of approval presents a commercial headwind, making the value proposition to payers more complex. The approval